CureVac inks lung cancer vax partnership with Boehringer; DynPort sues Lonza over vaccine manufacturing subcontract;

> CureVac has banked a $45 million upfront payment from Boehringer Ingelheim to partner its therapeutic lung cancer vaccine with the German pharma's Gilotrif. More

> DynPort Vaccine, which develops vaccines for the military, has sued Lonza Biologics, alleging the company backed out of a subcontract to manufacture a vaccine and made off with $18.9 million. Report (sub. req.)

> A law firm representing the bulk of patients who developed narcolepsy after being vaccinated with GlaxoSmithKline's ($GSK) swine flu shot Pandemrix does not expect to go to trial before March of 2016. Report

> The Japanese Global Health Fund has awarded a combined $33.5 million to companies and orgnizations including Takeda, Eisai and the PATH Malaria Vaccine Initiative to fund vaccine and drug development for neglected diseases. Release

> GlaxoSmithKline's vaccines unit has agreed to pay a civil penalty of $172,900 to resolve a Clean Air Act violation from a facility in Hamilton, MT. Report

> With Texas Gov. Rick Perry in attendance, Texas A&M University will dedicate a pandemic influenza vaccine facility Thursday. More

And Finally... Vaccination rates in elite Los Angeles schools are now worse than in Southern Sudan. More

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.